Select Page

Menopause Dry Eyes Testimonials

Astounded

I am astounded at how quickly this product helped my eyes. After taking only three doses, the pain in my eye was gone. Bless you. Bless you.

*Note: Results may vary.*

Singermom

Noticed A Huge Difference

I was suffering from hormonally-related dry eye symptoms, exacerbated by a powerful air-conditioning/heating system in my office. I tried every kind of drop on the market to no avail and was considering getting a prescription. Then I heard about TheraLife and decided to give it a try. I noticed a huge difference within a couple of days, and 6 months later I had virtually no symptoms at all. I’ve been taking TheraLife regularly for a few years now and my eyes feel great! I truly can’t recommend this product highly enough.

*Note: Results may vary.*

Julie S.

Energized and Happy Again

I am a 64 year old female engineer. I use the computer daily. I had dry eyes for more than 20 years. It had not bothered me too much until last spring. One morning while driving to work, I felt a sudden sharp pain in my right eye. It was like someone stabbed my eye with a knife. Since then my eyes were constantly tearing and burning. I visited four eye doctors. They examined my eyes and concluded that I had severe eye inflammation (Blepharitis) due to dry eye and allergy. They prescribed expensive eye drops like Pataday and eye gels. The medications did not help much, they just gave me temporary relief of the symptoms. I was afraid of sunlight and had a hard time driving even with double sun glasses. It bothered me so much that I considered retiring from my job. One day my son called me and told me that his co-worker had similar problems and that he claimed Theralife Eye supplement saved his life. My son sent me two bottles of Theralife Eye supplement as Christmas gift. I followed Dr. Yang’s instructions, and after about a month I started to feel my own tear film come back and started to have more tolerance toward sunlight. The tearing and burning sensation gradually faded away. I consulted with Dr. Yang from time to time. She recommended I take Theralife women’s menopausal support formula to ease my dry mouth and heart palpitation problem. She encouraged me to exercise and cut back on caffeine intake. Now I feel energized and happy again. Thank you, Dr. Yang!

*Note: Results may vary.*

Judy
References
1. Sullivan DA. Gender and menopause dry eye. In: Research to Prevent Blindness Science Writers Seminar. New York, NY: Research to Prevent Blindness; 1997:57-60.
2. Lemp MA. Epidemiology and classification of menopause dry eye.  Adv Exp Med Biol.1998;438:791-803.Google Scholar
3. Gilbard JP. Menopause Dry eye disorders. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. Philadelphia, Pa: WB Saunders; 1994:257-276.
4. McMonnies CW, Ho H. Patient history in screening for dry eye conditions.  J Am Optom Assoc.1987;58:296-301.Google Scholar
5. Nelson JD, Helms H, Fiscella R, Southwell Y, Hirsch JD. A new look at menopause dry eye disease and its treatment.  Adv Ther.2000;17:84-93.Google Scholar
6. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States.  Ann Intern Med.1999;130:545-553.Google Scholar
7. Belchetz PE. Hormonal treatment of postmenopausal women.  N Engl J Med.1994;330:1062-1071.Google Scholar
8. The Writing Group for the PEPI Trial.  Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.  JAMA.1995;273:199-208. [published erratum appears in JAMA. 1995;274:1676].Google Scholar
9. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence.  Prev Med.1991;20:47-63.Google Scholar
10. The Writing Group for the PEPI Trial.  Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial.  JAMA.1996;276:1389-1396.Google Scholar
11. Grodstein F, Stampfer MJ, Colditz GA.  et al.  Postmenopausal hormone therapy and mortality.  N Engl J Med.1997;336:1769-1775.Google Scholar
12. Hulley S, Grady D, Bush T.  et al. for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.  JAMA.1998;280:605-613.Google Scholar
13. Tavani A, La Vecchia C. The adverse effects of hormone replacement therapy.  Drugs Aging.1999;14:347-357.Google Scholar
14. Taskinen MR. Oestrogen replacement therapy for menopause dry eyes and coronary heart disease.  Ann Med.1998;30:443-451.Google Scholar
15. Sullivan DA, Wickham LA, Rocha EM, Kelleher RS, da Silveira LA, Toda I. Influence of gender, sex steroid hormones, and the hypothalamic-pituitary axis on the structure and function of the lacrimal gland.  Adv Exp Med Biol.1998;438:11-42.Google Scholar
16. Gurwood AS, Gurwood I, Gubman DT, Brzezicki LJ. Idiosyncratic ocular symptoms associated with the estradiol transdermal estrogen replacement patch system.  Optom Vis Sci.1995;72:29-33.Google Scholar
17. Sato EH, Sullivan DA. Comparative influence of steroid hormones and immunosuppressive agents on autoimmune expression in lacrimal glands of a female mouse model of Sjogren's syndrome.  Invest Ophthalmol Vis Sci.1994;35:2632-2642.Google Scholar
18. Rexrode KM, Lee I, Cook NR, Hennekens CH, Buring JE. Baseline characteristic of participants in the Women's Health Study.  J Womens Health Gend Based Med.2000;9:19-27.Google Scholar
19. Oden NL, Lilienfeld DE, Lemp MA, Nelson JD, Ederer F. Sensitivity and specificity of a screening questionnaire for dry eye.  Adv Exp Med Biol.1998;438:807-820.Google Scholar
20. Sullivan DA, Rocha EM, Ullman MD.  et al.  Androgen regulation of the meibomian gland.  Adv Exp Med Biol.1998;438:327-331.Google Scholar
21. Sullivan DA, Wickham LA, Rocha EM.  et al.  Androgens and dry eye in Sjogren's syndrome.  Ann N Y Acad Sci.1999;876:312-324.Google Scholar
22. Davis S. Testosterone deficiency in women.  J Reprod Med.2001;46(3 suppl):291-296.Google Scholar
23. Nichols KK, Nichols JJ, Zadnik K. Frequency of dry eye diagnostic test procedures used in various modes of ophthalmic practice.  Cornea.2000;19:477-482.Google Scholar
24. Korb DR. Survey of preferred tests for diagnosis of the tear film and dry eye.  Cornea.2000;19:483-486.Google Scholar
25. Taylor HR, Louis WJ. Significance of tear function test abnormalities.  Ann Ophthalmol.1980;12:531-535.Google Scholar
26. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome.  Arch Ophthalmol.2000;118:1264-1268.Google Scholar
27. McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR. The epidemiology of dry eye in Melbourne, Australia.  Ophthalmology.1998;105:1114-1119.Google Scholar
28. Caffery BE, Richter D, Simpson T, Fonn D, Doughty M, Gordon K. CANDEES: the Canadian Dry Eye Epidemiology Study.  Adv Exp Med Biol.1998;438:805-806.Google Scholar
29. Hunter DJ, Colditz GA, Stampfer MJ, Rosner B, Willett WC, Speizer FE. Risk factors for basal cell carcinoma in a prospective cohort of women.  Ann Epidemiol.1990;1:13-23.Google Scholar
30. Frieling UM, Schaumberg DA, Kupper TS, Muntwyler J, Hennekens CH. A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician's health study.  Arch Dermatol.2000;136:179-184.Google Scholar

Testimonials

Pin It on Pinterest